120 related articles for article (PubMed ID: 4042992)
1. Twenty-four hour secretory pattern of thyroid-stimulating hormone in hyperprolactinemic women with pituitary microadenoma.
Seki K; Uesato T; Kato K; Shima K
Endocrinol Jpn; 1985 Jun; 32(3):369-73. PubMed ID: 4042992
[TBL] [Abstract][Full Text] [Related]
2. Twenty-four hour secretory pattern of growth hormone in hyperprolactinemic women with pituitary microadenoma.
Seki K; Kato K; Shima K
Endocrinol Jpn; 1987 Feb; 34(1):129-32. PubMed ID: 3608911
[TBL] [Abstract][Full Text] [Related]
3. Evidence for increased dopaminergic inhibition of secretion of thyroid-stimulating hormone in hyperprolactinemic patients with pituitary microadenoma.
Quigley ME; Yen SS
Am J Obstet Gynecol; 1980 Jul; 137(6):653-5. PubMed ID: 7395929
[TBL] [Abstract][Full Text] [Related]
4. Functional evaluation of the adenohypophysis with metoclopramide in hyperprolactinemic-amenorrheic women in relation to radiological findings on the sella turcica.
Seki K; Uesato T; Kato K; Shima K
Endocrinol Jpn; 1984 Dec; 31(6):733-9. PubMed ID: 6532792
[TBL] [Abstract][Full Text] [Related]
5. Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect.
Rodriguez-Arnao MD; Peters JR; Foord SM; Dieguez C; Edwards C; Gomez-Pan A; Hall R; Newcombe RG; Scanlon MF
J Clin Endocrinol Metab; 1983 Nov; 57(5):975-80. PubMed ID: 6619271
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients.
De Marinis L; Mancini A; Minnielli S; Masala R; Anile C; Maira G; Barbarino A
Metabolism; 1985 Oct; 34(10):917-22. PubMed ID: 4046835
[TBL] [Abstract][Full Text] [Related]
7. Increased thyroid-stimulating hormone response to thyrotropin-releasing hormone in hyperprolactinemic women.
Seki K; Kato K
J Clin Endocrinol Metab; 1985 Dec; 61(6):1138-41. PubMed ID: 3932450
[TBL] [Abstract][Full Text] [Related]
8. Parallelism in the luteinizing hormone responses to opioid and dopamine antagonists in hyperprolactinemic women with pituitary microadenoma.
Seki K; Kato K; Shima K
J Clin Endocrinol Metab; 1986 Nov; 63(5):1225-8. PubMed ID: 3760121
[TBL] [Abstract][Full Text] [Related]
9. Responses of growth hormone to metoclopramide in normal women and amenorrheic women with or without hyperprolactinemia.
Seki K; Kato K
Endocrinol Jpn; 1986 Oct; 33(5):721-5. PubMed ID: 3830074
[TBL] [Abstract][Full Text] [Related]
10. The inability of dynamic tests of prolactin and TSH secretion to differentiate between tumorous and non-tumorous hyperprolactinemia.
Prescott RW; Johnston DG; Taylor PK; Haigh J; Weightman DR; Hall K; Cook DB
J Endocrinol Invest; 1985 Feb; 8(1):49-54. PubMed ID: 3921596
[TBL] [Abstract][Full Text] [Related]
11. Effects of a dopamine antagonist (metoclopramide) on the release of beta-endorphin, ACTH and cortisol in hyperprolactinemic-amenorrheic women.
Seki K; Mitsui C; Nagata I
Gynecol Obstet Invest; 1995; 40(1):42-5. PubMed ID: 7557642
[TBL] [Abstract][Full Text] [Related]
12. Postoperative evaluation of dopaminergic tone in prolactinoma patients. II. Plasma thyrotropin response to metoclopramide.
De Marinis L; Mancini A; Maira G; Anile C; Menini E; Barbarino A
J Clin Endocrinol Metab; 1984 Mar; 58(3):405-9. PubMed ID: 6693543
[TBL] [Abstract][Full Text] [Related]
13. Defective dopaminergic regulation of prolactin secretion in patients with hyperprolactinemia.
Serri O; Beauregard H; Somma M; Comtois R; Jilwan N; Hardy J
Clin Invest Med; 1988 Dec; 11(6):387-91. PubMed ID: 3229037
[TBL] [Abstract][Full Text] [Related]
14. Levels of glucose and insulin during twenty-four hours in hyperprolactinemic women with pituitary microadenoma.
Seki K; Nagata I
Gynecol Obstet Invest; 1991; 31(4):222-5. PubMed ID: 1885092
[TBL] [Abstract][Full Text] [Related]
15. Catecholamines and pituitary-function. V. Effect of low-dose dopamine infusion on basal and gonadotropin-releasing hormone stimulated gonadotropin release in normal cycling women and patients with hyperprolactinemic amenorrhea.
Nicoletti I; Ambrosi F; Giammartino C; Fedeli L; Mannarelli C; Filipponi P
Horm Metab Res; 1986 Jul; 18(7):479-84. PubMed ID: 3091473
[TBL] [Abstract][Full Text] [Related]
16. Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function.
Scanlon MF; Rodriguez-Arnao MD; McGregor AM; Weightman D; Lewis M; Cook DB; Gomez-Pan A; Hall R
Clin Endocrinol (Oxf); 1981 Feb; 14(2):133-43. PubMed ID: 6790201
[TBL] [Abstract][Full Text] [Related]
17. Hyperthyroidism due to a thyroid-stimulating hormone (TSH)-secreting pituitary adenoma associated with functional hyperprolactinaemia. A case report.
Savastano S; Lombardi G; Merola B; Miletto P; Di Prisco B; Manco A; Beck-Peccoz P; Faglia G
Acta Endocrinol (Copenh); 1987 Dec; 116(4):452-8. PubMed ID: 3425160
[TBL] [Abstract][Full Text] [Related]
18. Reduced dopaminergic inhibition of thyrotropin release in hyperprolactinemic ovulatory women.
Larrea F; Escorza A; Valencia X; Méndez I; Schiavon R; Forsbach G
Rev Invest Clin; 1991; 43(4):293-8. PubMed ID: 1798861
[TBL] [Abstract][Full Text] [Related]
19. Prl, TSH, GH and LH responses to metoclopramide and breast-feeding in normal and hyperprolactinaemic women.
Andersen AN; Tabor A
Acta Endocrinol (Copenh); 1982 Jun; 100(2):177-83. PubMed ID: 7202316
[TBL] [Abstract][Full Text] [Related]
20. [The reaction of the hypophysis to thyroliberin and metoclopramide in women with hyperprolactinemia].
Tkachenko NN; Potin VV; Beskrovnyĭ SV; Nosova LG
Probl Endokrinol (Mosk); 1990; 36(2):35-40. PubMed ID: 2114023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
